# Sergio Valente

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 136 papers | 6,320 citations | 50244 46 h-index | 82499 72 g-index |
| 144 all docs | 144 docs citations | 144 times ranked | 9857 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | TNF/p38Î±/Polycomb Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle Regeneration. Cell Stem Cell, 2010, 7, 455-469. | 5.2 | 346 |
| 2 | Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Medicinal Research Reviews, 2005, 25, 261-309. | 5.0 | 306 |
| 3 | Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. Journal of the American Chemical Society, 2010, 132, 6827-6833. | 6.6 | 261 |
| 4 | Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue. Diabetes, 2013, 62, 732-742. | 0.3 | 196 |
| 5 | Oxidative Stress and Epigenetic Regulation in Ageing and Age-Related Diseases. International Journal of Molecular Sciences, 2013, 14, 17643-17663. | 1.8 | 183 |
| 6 | Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53. | 5.8 | 175 |
| 7 | Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5496-5504. | 2.9 | 147 |
| 8 | Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 2279-2290. | 2.9 | 133 |
| 9 | Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€“MEF2 complexes. EMBO Reports, 2009, 10, 776-782. | 2.0 | 125 |
| 10 | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clinical Epigenetics, 2017, 9, 59. | 1.8 | 118 |
| 11 | Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling. Circulation Research, 2008, 102, 51-58. | 2.0 | 114 |
| 12 | Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells. Journal of Medicinal Chemistry, 2014, 57, 701-713. | 2.9 | 111 |
| 13 | Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities. Journal of Medicinal Chemistry, 2014, 57, 42-55. | 2.9 | 105 |
| 14 | 1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6259-6265. | 2.9 | 102 |
| 15 | "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology, 2009, 6, 52. | 0.9 | 100 |
| 16 | Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 1908-1919. | 1.5 | 95 |
| 17 | Six Years (2012â€“2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2â€Pyridone Compounds. Chemical Record, 2018, 18, 1818-1832. | 2.9 | 76 |
| 18 | Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise. Current Pharmaceutical Design, 2009, 15, 3940-3957. | 0.9 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A Nitric Oxide-dependent Cross-talk between Class I and III Histone Deacetylases Accelerates Skin Repair. Journal of Biological Chemistry, 2013, 288, 11004-11012. | 1.6 | 74 |
| 20 | The Innovative Potential of Statins in Cancer: New Targets for New Therapies. Frontiers in Chemistry, 2020, 8, 516. | 1.8 | 73 |
| 21 | Interplay among nucleosomal DNA, histone tails, and corepressor CoREST underlies LSD1-mediated H3 demethylation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2752-2757. | 3.3 | 71 |
| 22 | Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517. | 2.9 | 70 |
| 23 | 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studiesâ€Î". Journal of Medicinal Chemistry, 2004, 47, 1351-1359. | 2.9 | 65 |
| 24 | Novel 3,5-Bis(bromohydroxybenzylidene)piperidin-4-ones as Coactivator-Associated Arginine Methyltransferase 1 Inhibitors: Enzyme Selectivity and Cellular Activity. Journal of Medicinal Chemistry, 2011, 54, 4928-4932. | 2.9 | 65 |
| 25 | Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 599-613. | 2.5 | 63 |
| 26 | A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. Redox Biology, 2020, 32, 101466. | 3.9 | 62 |
| 27 | 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2and/or -C4Substitutions on Biological Activityâ€. Journal of Medicinal Chemistry, 2004, 47, 1098-1109. | 2.9 | 61 |
| 28 | The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene, 2014, 33, 4173-4184. | 2.6 | 61 |
| 29 | Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer, 2014, 14, 139. | 1.1 | 61 |
| 30 | 1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 1471-1491. | 2.9 | 60 |
| 31 | Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells. Bioorganic and Medicinal Chemistry, 2012, 20, 1584-1593. | 1.4 | 58 |
| 32 | Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29. PLoS ONE, 2013, 8, e55786. | 1.1 | 56 |
| 33 | Sirtuin modulators control reactive gliosis in an in vitro model of AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Pharmacology, 2014, 5, 89. | 1.6 | 56 |
| 34 | Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acidâ€“induced differentiation. Science Advances, 2020, 6, eaax2746. | 4.7 | 56 |
| 35 | DNA Methyltransferases Inhibitors from Natural Sources. Current Topics in Medicinal Chemistry, 2015, 16, 680-696. | 1.0 | 56 |
| 36 | Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells. Journal of Medicinal Chemistry, 2015, 58, 4073-4079. | 2.9 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents. ACS Chemical Biology, 2015, 10, 2589-2597. | 1.6 | 54 |
| 38 | HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. Journal of Molecular Endocrinology, 2010, 45, 219-228. | 1.1 | 53 |
| 39 | Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. ChemMedChem, 2007, 2, 987-991. | 1.6 | 52 |
| 40 | Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. European Neuropsychopharmacology, 2015, 25, 2036-2048. | 0.3 | 51 |
| 41 | Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors. Antimicrobial Agents and Chemotherapy, 2004, 48, 1435-1436. | 1.4 | 50 |
| 42 | Nitric Oxide Determines Mesodermic Differentiation of Mouse Embryonic Stem Cells by Activating Class IIa Histone Deacetylases: Potential Therapeutic Implications in a Mouse Model of Hindlimb Ischemia. Stem Cells, 2010, 28, 431-442. | 1.4 | 50 |
| 43 | Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2014, 86, 352-363. | 2.6 | 50 |
| 44 | New Insights on the Mechanism of Quinoline-based DNA Methyltransferase Inhibitors. Journal of Biological Chemistry, 2015, 290, 6293-6302. | 1.6 | 50 |
| 45 | Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Gastroenterology, 2021, 161, 1584-1600. | 0.6 | 50 |
| 46 | Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Medicinal Chemistry Letters, 2020, 11, 977-983. | 1.3 | 49 |
| 47 | The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget, 2017, 8, 68557-68570. | 0.8 | 49 |
| 48 | HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2030-2038. | 1.9 | 48 |
| 49 | Targeting Lysine Deacetylases (KDACs) in Parasites. PLoS Neglected Tropical Diseases, 2015, 9, e0004026. | 1.3 | 47 |
| 50 | Sirtuin modulators: an updated patent review (2012 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 5-15. | 2.4 | 46 |
| 51 | LSD1 inhibitors: a patent review (2010-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 565-580. | 2.4 | 46 |
| 52 | Aurones: interesting natural and synthetic compounds with emerging biological potential. Natural Product Communications, 2012, 7, 389-94. | 0.2 | 45 |
| 53 | Identification of novel quinazoline derivatives as potent antiplasmodial agents. European Journal of Medicinal Chemistry, 2019, 161, 277-291. | 2.6 | 44 |
| 54 | 3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds. Journal of Chemical Information and Modeling, 2006, 46, 1420-1430. | 2.5 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Novel benzofuranâ€“chromone and â€“coumarin derivatives: synthesis and biological activity in K562 human leukemia cells. MedChemComm, 2013, 4, 1571. | 3.5 | 41 |
| 56 | Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 â€“ 2013). Expert Opinion on Therapeutic Patents, 2014, 24, 401-415. | 2.4 | 40 |
| 57 | EZH2 inhibitors: a patent review (2014-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 797-813. | 2.4 | 40 |
| 58 | Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2284-93. | 3.3 | 39 |
| 59 | Altered modulation of lamin A/Câ€HDAC2 interaction and p21 expression during oxidative stress response in HGPS. Aging Cell, 2018, 17, e12824. | 3.0 | 39 |
| 60 | Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5827-5830. | 1.0 | 35 |
| 61 | Novel inhibitors of human histone deacetylases: Design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3797-3801. | 1.0 | 35 |
| 62 | The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells. Scientific Reports, 2019, 9, 15925. | 1.6 | 35 |
| 63 | Population and segregation data on 17 Y-STRs: results of a GEP-ISFG collaborative study. International Journal of Legal Medicine, 2008, 122, 529-533. | 1.2 | 34 |
| 64 | Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1H-Pyrrol-3-yl)-2-oxazolidinones. Journal of Medicinal Chemistry, 2011, 54, 8228-8232. | 2.9 | 33 |
| 65 | Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. Cancer Research, 2014, 74, 2328-2339. | 0.4 | 33 |
| 66 | MC1568 inhibits HDAC6/8 activity and influenza A virus replication in lung epithelial cells: role of Hsp90 acetylation. Future Medicinal Chemistry, 2016, 8, 2017-2031. | 1.1 | 33 |
| 67 | A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892. | 1.9 | 33 |
| 68 | Evaluation of Histone Deacetylases as Drug Targets in Huntingtonâ€™s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.. PLOS Currents, 2010, 2, RRN1172. | 1.4 | 33 |
| 69 | Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. Journal of Molecular Cell Biology, 2014, 6, 116-127. | 1.5 | 31 |
| 70 | Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. Molecular Pharmacology, 2007, 72, 1111-1123. | 1.0 | 30 |
| 71 | Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68. | 1.8 | 30 |
| 72 | Detrimental Effect of Class-selective Histone Deacetylase Inhibitors during Tissue Regeneration following Hindlimb Ischemia. Journal of Biological Chemistry, 2013, 288, 22915-22929. | 1.6 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | A novel coumarinâ€quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death. Molecular Carcinogenesis, 2015, 54, 229-241. | 1.3 | 29 |
| 74 | Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. European Journal of Medicinal Chemistry, 2015, 94, 163-174. | 2.6 | 28 |
| 75 | Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie, 2012, 94, 2308-2313. | 1.3 | 27 |
| 76 | Chalcone-Coumarin Derivatives as Potential Anti-Cancer Drugs: An in vitro and in vivo Investigation. Anti-Cancer Agents in Medicinal Chemistry, 2013, 14, 963-974. | 0.9 | 27 |
| 77 | Histone postâ€translational modifications by HPLCâ€ESIâ€MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics, 2009, 9, 5437-5445. | 1.3 | 25 |
| 78 | Aurones: Interesting Natural and Synthetic Compounds with Emerging Biological Potential. Natural Product Communications, 2012, 7, 1934578X1200700. | 0.2 | 25 |
| 79 | Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2â€“EED Interaction. Journal of Medicinal Chemistry, 2021, 64, 8194-8207. | 2.9 | 25 |
| 80 | Polycomb Repressive Complex 2 Modulation through the Development of EZH2â€“EED Interaction Inhibitors and EED Binders. Journal of Medicinal Chemistry, 2021, 64, 11774-11797. | 2.9 | 25 |
| 81 | New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. International Journal of Biochemistry and Cell Biology, 2009, 41, 235-247. | 1.2 | 24 |
| 82 | Pyrrole- and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells. MedChemComm, 2015, 6, 665-670. | 3.5 | 24 |
| 83 | Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. European Journal of Medicinal Chemistry, 2017, 134, 316-333. | 2.6 | 24 |
| 84 | Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors. Medicinal Chemistry, 2005, 1, 245-254. | 0.7 | 23 |
| 85 | Facile synthesis of 4-acetyl-coumarins, -thiocoumarin and -quinolin-2(1H)-one via very high Î±-regioselective Heck coupling on tosylates. Tetrahedron Letters, 2011, 52, 3429-3432. | 0.7 | 23 |
| 86 | HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal. Scientific Reports, 2018, 8, 8492. | 1.6 | 23 |
| 87 | Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology, 2019, 50, 89-100. | 2.8 | 23 |
| 88 | Statins and Histone Deacetylase Inhibitors Affect Lamin A/C â€“ Histone Deacetylase 2 Interaction in Human Cells. Frontiers in Cell and Developmental Biology, 2019, 7, 6. | 1.8 | 23 |
| 89 | Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2530-2535. | 1.0 | 22 |
| 90 | Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice. Neuroscience Letters, 2017, 656, 120-125. | 1.0 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice. Neuroscience, 2018, 379, 228-238. | 1.1 | 22 |
| 92 | Aroyl-Pyrrolyl Hydroxyamides: Influence of Pyrrole C4-Phenylacetyl Substitution on Histone Deacetylase Inhibition. ChemMedChem, 2006, 1, 225-237. | 1.6 | 20 |
| 93 | Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1Î² and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model. Autoimmunity, 2016, 49, 155-165. | 1.2 | 20 |
| 94 | Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. Molecular Neurobiology, 2019, 56, 8018-8034. | 1.9 | 20 |
| 95 | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. Frontiers in Pharmacology, 2020, 11, 1230. | 1.6 | 20 |
| 96 | Application of 3Î¼m particle-based amylose-derived chiral stationary phases for the enantioseparation of potential histone deacetylase inhibitors. Journal of Chromatography A, 2011, 1218, 8394-8398. | 1.8 | 19 |
| 97 | Tranylcypromineâ€Based LSD1 Inhibitors: Structureâ€Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. ChemMedChem, 2020, 15, 643-658. | 1.6 | 18 |
| 98 | Novel Cinnamyl Hydroxyamides and 2â€Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. ChemMedChem, 2011, 6, 698-712. | 1.6 | 17 |
| 99 | tertâ€Butylcarbamateâ€Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. ChemMedChem, 2013, 8, 800-811. | 1.6 | 16 |
| 100 | Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Medicinal Chemistry Letters, 2015, 6, 173-177. | 1.3 | 16 |
| 101 | Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene. Human Genetics, 2020, 139, 227-245. | 1.8 | 16 |
| 102 | Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells. European Journal of Medicinal Chemistry, 2019, 163, 722-735. | 2.6 | 15 |
| 103 | Histoneâ€deacetylase 8 drives the immune response and the growth of glioma. Glia, 2021, 69, 2682-2698. | 2.5 | 14 |
| 104 | Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. International Journal of Biochemistry and Cell Biology, 2007, 39, 1510-1522. | 1.2 | 13 |
| 105 | Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170150. | 1.8 | 13 |
| 106 | Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 2018, 9, 25647-25660. | 0.8 | 13 |
| 107 | Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni. ACS Infectious Diseases, 2022, 8, 1356-1366. | 1.8 | 13 |
| 108 | Reactivity of 4â€Vinylâ€2Hâ€1â€benzopyranâ€2â€ones in Dielsâ€“Alder Cycloaddition Reactions: Access to Coumarinâ€Based Polycycles with Cdc25 Phosphataseâ€Inhibiting Activity. European Journal of Organic Chemistry, 2013, 2013, 2869-2877. | 1.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Application of Small Epigenetic Modulators in Pediatric Medulloblastoma. Frontiers in Pediatrics, 2018, 6, 370. | 0.9 | 12 |
| 110 | Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. Theranostics, 2022, 12, 2427-2444. | 4.6 | 12 |
| 111 | Structureâ€“Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. ChemMedChem, 2017, 12, 1359-1368. | 1.6 | 11 |
| 112 | Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1339-1359. | 2.9 | 11 |
| 113 | Trends of LSD1 inhibitors in viral infections. Future Medicinal Chemistry, 2018, 10, 1133-1136. | 1.1 | 10 |
| 114 | Pyrroleâ€Based Hydroxamates and 2â€Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. ChemMedChem, 2009, 4, 1411-1415. | 1.6 | 9 |
| 115 | PRMT1 arginine methyltransferase accumulates in cytoplasmic bodies that respond to selective inhibition and DNA damage. European Journal of Histochemistry, 2014, 58, 2389. | 0.6 | 9 |
| 116 | Evaluation of Î”2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway. International Journal of Oncology, 2014, 45, 426-438. | 1.4 | 9 |
| 117 | Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447. | 1.7 | 8 |
| 118 | Novel Pyridineâ€Based Hydroxamates and 2â€²â€Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem, 2021, 16, 989-999. | 1.6 | 8 |
| 119 | Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead. MedChemComm, 2012, 3, 298-304. | 3.5 | 7 |
| 120 | Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibroâ€adipogenic progenitors. EMBO Reports, 2022, 23, e54721. | 2.0 | 7 |
| 121 | Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, 2018, 9, 25630-25646. | 0.8 | 5 |
| 122 | Synthesis and biochemical evaluation of (R)-5-acyloxymethyl- and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones as new anti-monoamine oxidase (anti-MAO) agents. Arkivoc, 2004, 2004, 32-43. | 0.3 | 5 |
| 123 | Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. Molecules, 2020, 25, 3122. | 1.7 | 4 |
| 124 | Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization. ACS Chemical Biology, 2020, 15, 1349-1357. | 1.6 | 4 |
| 125 | Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. Frontiers in Endocrinology, 2022, 13, . | 1.5 | 4 |
| 126 | Editorial: Molecular Mechanisms and New Therapeutic Targets in Epithelial to Mesenchymal Transition (EMT) and Fibrosis. Frontiers in Pharmacology, 2020, 10, 1556. | 1.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Editorial: Natural Product Epigenetic Modulators and Inhibitors. Frontiers in Pharmacology, 2021, 12, 651395. | 1.6 | 2 |
| 128 | Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 973-985. | 2.5 | 2 |
| 129 | Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€MEF2 complexes. EMBO Reports, 2020, 21, e51028. | 2.0 | 1 |
| 130 | Inhibition of PKCÎ¸ Improves Dystrophic Heart Phenotype and Function in a Novel Model of DMD Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 2256. | 1.8 | 1 |
| 131 | Histone Deacetylation in Epigenetics: An Attractive Target for Anticancer Therapy. ChemInform, 2005, 36, no. | 0.1 | 0 |
| 132 | Epigenetic Pharmacology in Regenerative Medicine (Epi-Drugs). , 2019, , 405-444. | | 0 |
| 133 | Lysine Methyltransferases and Their Inhibitors. Topics in Medicinal Chemistry, 2019, , 123-157. | 0.4 | 0 |
| 134 | Editorial: New Approaches to Tackle EMT and Fibrosis: From Epigenetics to Nanotechnology. Frontiers in Pharmacology, 2021, 12, 742777. | 1.6 | 0 |
| 135 | Natural Products Molten Together: Toward Multifunctional Hybrid Molecules with Specific Activities and Applications. , 2014, , 379-397. | | 0 |
| 136 | Abstract 2946: Effects of two novel quinoline-based non-nucleoside DNA methyltransferase inhibitors against bone sarcomas. , 2015, , . | | 0 |